卡托普利 T1462

Product Introduction
Bioactivity


英文名: Captopril

描述: Captopril (SA333) 是一种含巯基的，具有口服活性的血管紧张素转换酶(ACE)抑制剂 ，IC50=0.025 μM，广泛应用于高血压和充血性心力衰竭的研究。Captopril 也是NDM-1抑制剂，IC50=7.9 μM。

激酶实验: Binding assay: Cells are plated in 24-well plates and cultured until confluence. Before the experiment, the cells are washed three times with 0.5 mL per well of DMEM at room temperature. After removal of the medium, 400 μL binding DMEM is added and the plate is then left for 15 min at 37 ℃. For saturation binding assays cells are incubated with increasing concentrations [3H]Candesartan (final concentrations between 0.15 nM and 15 nM) in a final volume of 0.5 mL at 37 ℃ for 5 min to 180 min. For competition binding assays 50 μL of buffer or 50 μL of buffer containing increasing concentrations of unlabelled Candesartan is added. After 30 min, 50 μL of buffer containing [3H]Candesartan (final concentration 1.1 nM) or [3H]Candesartan (final concentration 1.0 nM) is added, and the cells are further incubated for 30 min at 37 ℃.

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: H2O : 21.7 mg/mL (100 mM)
DMSO : 50 mg/mL (230.11 mM)


关键字: antihypertensive | Angiotensin-converting Enzyme (ACE) | Captopril | failure | SQ 14534 | inhibit | oral | SQ14534 | congestive | hypertension | Inhibitor | SA 333 | SQ14225 | SQ-14225 | SA-333 | heart

相关产品: Fimasartan | Resorcinolnaphthalein | Temocapril hydrochloride | Olmesartan | VTP-27999 TFA | Alacepril | Alamandine TFA | H-Val-Pro-Pro-OH | Moexipril hydrochloride | BTB06584

相关库: Drug Repurposing Compound Library | Approved Drug Library | Anti-Cancer Drug Library | Clinical Compound Library | Membrane Protein-targeted Compound Library | Anti-Metabolism Disease Compound Library | Inhibitor Library | Anti-Cancer Clinical Compound Library | Anti-Cancer Approved Drug Library | Orally Active Compound Library

卡托普利 T1462信息由TargetMol中国为您提供，如您想了解更多关于卡托普利 T1462报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途